6:20 PM
 | 
Sep 02, 2014
 |  BC Extra  |  Company News

Novo Nordisk discontinues inflammation R&D

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) is discontinuing all inflammatory disease R&D. Novo ended development of its lead compound in the space,

Read the full 92 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >